Ebiola Outbreak: How Did US Ebola Patients Get 'Experimental' Serum? — The 'Experimenter' Worked for the 'Defense Threat Reduction Agency'

Are 'mad scientists' working for the US military in the Ebola outbreak zone?

By Sydney Lupkin
Desperate to save the American Ebola patients in Liberia, Samaritan's Purse started researching experimental treatments last week, according to an official at the National Institutes of Health.

The organization called the Centers for Disease Control and Prevention, which referred it to an NIH employee deployed in Africa who would be familiar with the treatments.

"She was able to answer some questions and referred them to appropriate company and embassy contacts to pursue their interest in obtaining experimental product," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

He added that the NIH employee was not working in any official capacity for the NIH at the time. She was working for a team led by CDC and the Defense Threat Reduction Agency.

The experimental drug was manufactured by San Diego-based Mapp Biopharmaceuticals, according to the National Institute of Allergy and Infectious Diseases.

According to Mapp’s website, its Ebola drug is a “cocktail” of monoclonal antibodies, which had been proven to work in monkey studies.

Read More